Amedeo Smart

Free Medical Literature Service


 

Amedeo

COVID-19

  Free Subscription

Articles published in
Antiviral Res
    November 2021
  1. ZHAO J, Zhang G, Zhang Y, Yi D, et al
    2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.
    Antiviral Res. 2021;196:105209.
    >> Share

  2. SVILENOV HL, Sacherl J, Reiter A, Wolff LS, et al
    Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
    Antiviral Res. 2021 Nov 10:105197. doi: 10.1016/j.antiviral.2021.105197.
    >> Share

  3. QIU H, Yuan XY, Cabral T, Manguiat K, et al
    Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
    Antiviral Res. 2021 Nov 8:105206. doi: 10.1016/j.antiviral.2021.105206.
    >> Share

    October 2021
  4. WANG YT, Allen RD 3rd, Kim K, Shafee N, et al
    SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
    Antiviral Res. 2021 Oct 8:105185. doi: 10.1016/j.antiviral.2021.105185.
    >> Share

  5. DEY-RAO R, Smith GR, Timilsina U, Falls Z, et al
    A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
    Antiviral Res. 2021;195:105183.
    >> Share

    September 2021
  6. JULANDER JG, Demarest JF, Taylor R, Gowen BB, et al
    An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
    Antiviral Res. 2021 Sep 19:105180. doi: 10.1016/j.antiviral.2021.105180.
    >> Share

    August 2021
  7. GARCIA-DORIVAL I, Cuesta-Geijo MA, Barrado-Gil L, Galindo I, et al
    Identification of Niemann-Pick C1 protein as a potential novel SARS-CoV-2 intracellular target.
    Antiviral Res. 2021 Aug 24:105167. doi: 10.1016/j.antiviral.2021.105167.
    >> Share

  8. ESCAFFRE O, Freiberg AN
    Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells.
    Antiviral Res. 2021 Aug 9:105162. doi: 10.1016/j.antiviral.2021.105162.
    >> Share

  9. LEACH A, Ilca FT, Akbar Z, Ferrari M, et al
    A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Antiviral Res. 2021 Aug 7:105147. doi: 10.1016/j.antiviral.2021.105147.
    >> Share

  10. ISON MG, Hayden FG, Hay AJ, Gubareva LV, et al
    Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.
    Antiviral Res. 2021;194:105158.
    >> Share

    July 2021
  11. KASPRZYK R, Spiewla TJ, Smietanski M, Golojuch S, et al
    Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.
    Antiviral Res. 2021;193:105142.
    >> Share

  12. TOURET F, Driouich JS, Cochin M, Petit PR, et al
    Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
    Antiviral Res. 2021;193:105137.
    >> Share

  13. GAN ES, Syenina A, Linster M, Ng B, et al
    A mouse model of lethal respiratory dysfunction for SARS-CoV-2 infection.
    Antiviral Res. 2021;193:105138.
    >> Share

  14. PERSOONS L, Vanderlinden E, Vangeel L, Wang X, et al
    Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues.
    Antiviral Res. 2021 Jul 1:105127. doi: 10.1016/j.antiviral.2021.105127.
    >> Share

    June 2021
  15. DO TND, Donckers K, Vangeel L, Chatterjee AK, et al
    A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents.
    Antiviral Res. 2021 Jun 26:105122. doi: 10.1016/j.antiviral.2021.105122.
    >> Share

  16. KASHYAP T, Murray J, Walker CJ, Chang H, et al
    Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
    Antiviral Res. 2021 Jun 19:105115. doi: 10.1016/j.antiviral.2021.105115.
    >> Share

    May 2021
  17. PAULL JRA, Heery GP, Bobardt MD, Castellarnau A, et al
    Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
    Antiviral Res. 2021 May 16:105089. doi: 10.1016/j.antiviral.2021.105089.
    >> Share

    April 2021
  18. ZHAO J, Guo S, Yi D, Li Q, et al
    A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Antiviral Res. 2021;190:105078.
    >> Share

  19. DU R, Cooper L, Chen Z, Lee H, et al
    Discovery of Chebulagic Acid and Punicalagin as Novel Allosteric Inhibitors of SARS-CoV-2 3CL(pro).
    Antiviral Res. 2021 Apr 16:105075. doi: 10.1016/j.antiviral.2021.105075.
    >> Share

    March 2021
  20. CICCOSANTI F, Di Rienzo M, Romagnoli A, Colavita F, et al
    Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection.
    Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064.
    >> Share

  21. MILANI M, Donalisio M, Bonotto RM, Schneider E, et al
    Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
    Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055.
    >> Share

  22. KUMAR R, Afsar M, Khandelwal N, Chander Y, et al
    Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.
    Antiviral Res. 2021 Mar 9:105056. doi: 10.1016/j.antiviral.2021.105056.
    >> Share

    February 2021
  23. MARTIN R, Li J, Parvangada A, Perry J, et al
    Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir.
    Antiviral Res. 2021 Feb 4:105033. doi: 10.1016/j.antiviral.2021.105033.
    >> Share

    January 2021
  24. LIU C, Boland S, Scholle MD, Bardiot D, et al
    Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development.
    Antiviral Res. 2021 Jan 27:105020. doi: 10.1016/j.antiviral.2021.105020.
    >> Share

  25. ZHU Q, Zhang Y, Wang L, Yao X, et al
    Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
    Antiviral Res. 2021 Jan 11:105015. doi: 10.1016/j.antiviral.2021.105015.
    >> Share

  26. MULLER C, Obermann W, Karl N, Wendel HG, et al
    The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
    Antiviral Res. 2021;186:105012.
    >> Share

    December 2020
  27. SUN X, Li L, Pan L, Wang Z, et al
    Infectious bronchitis virus: Identification of Gallus gallus APN high-affinity ligands with antiviral effects.
    Antiviral Res. 2020 Dec 16:104998. doi: 10.1016/j.antiviral.2020.104998.
    >> Share

  28. GAN HJ, Harikishore A, Lee J, Jeon S, et al
    Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
    Antiviral Res. 2020;185:104996.
    >> Share

    November 2020
  29. GALINDO I, Garaigorta U, Lasala F, Cuesta-Geijo MA, et al
    Antiviral drugs targeting endosomal membrane proteins inhibit distant animal and human pathogenic viruses.
    Antiviral Res. 2020 Nov 26:104990. doi: 10.1016/j.antiviral.2020.104990.
    >> Share

  30. SVENNINGSEN EB, Thyrsted J, Blay-Cadanet J, Liu H, et al
    Ionophore antibiotic X-206 is a potent inhibitor of SARS-CoV-2 infection in vitro.
    Antiviral Res. 2020 Nov 25:104988. doi: 10.1016/j.antiviral.2020.104988.
    >> Share

  31. ZHANG Y, Song W, Chen S, Yuan Z, et al
    A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
    Antiviral Res. 2020 Nov 17:104974. doi: 10.1016/j.antiviral.2020.104974.
    >> Share

    October 2020
  32. CHOI SW, Shin JS, Park SJ, Jung E, et al
    Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Antiviral Res. 2020 Oct 19:104955. doi: 10.1016/j.antiviral.2020.104955.
    >> Share

    September 2020
  33. THEERAWATANASIRIKUL S, Kuo CJ, Phecharat N, Chootip J, et al
    Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
    Antiviral Res. 2020 Sep 7:104927. doi: 10.1016/j.antiviral.2020.104927.
    >> Share

  34. GURARD-LEVIN ZA, Liu C, Jekle A, Jaisinghani R, et al
    Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Antiviral Res. 2020 Sep 4:104924. doi: 10.1016/j.antiviral.2020.104924.
    >> Share

    August 2020
  35. KONKOLOVA E, Dejmek M, Hrebabecky H, Sala M, et al
    Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
    Antiviral Res. 2020 Aug 4:104899. doi: 10.1016/j.antiviral.2020.104899.
    >> Share

  36. JEON YJ, Gil CH, Jo A, Won J, et al
    The influence of interferon-lambda on restricting Middle East Respiratory Syndrome Coronavirus replication in the respiratory epithelium.
    Antiviral Res. 2020;180:104860.
    >> Share

    July 2020
  37. OKAMOTO M, Toyama M, Baba M
    The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 30:104902. doi: 10.1016/j.antiviral.2020.104902.
    >> Share

  38. CONZELMANN C, Gilg A, Gross R, Schutz D, et al
    An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection.
    Antiviral Res. 2020 Jul 29:104882. doi: 10.1016/j.antiviral.2020.104882.
    >> Share

  39. PRASANTH KR, Hirano M, Fagg WS, McAnarney ET, et al
    Topoisomerase III-ss is required for efficient replication of positive-sense RNA viruses.
    Antiviral Res. 2020 Jul 28:104874. doi: 10.1016/j.antiviral.2020.104874.
    >> Share

  40. GALLIAN P, Pastorino B, Morel P, Chiaroni J, et al
    Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors.
    Antiviral Res. 2020 Jul 14:104880. doi: 10.1016/j.antiviral.2020.104880.
    >> Share

  41. PIZZORNO A, Padey B, Dubois J, Julien T, et al
    In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Antiviral Res. 2020 Jul 14:104878. doi: 10.1016/j.antiviral.2020.104878.
    >> Share

  42. VENISSE N, Peytavin G, Bouchet S, Gagnieu MC, et al
    Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
    Antiviral Res. 2020 Jul 10:104866. doi: 10.1016/j.antiviral.2020.104866.
    >> Share

  43. PAN X, Zhou P, Fan T, Wu Y, et al
    Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Jul 10:104868. doi: 10.1016/j.antiviral.2020.104868.
    >> Share

  44. KIM SY, Jin W, Sood A, Montgomery DW, et al
    Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
    Antiviral Res. 2020 Jul 9:104873. doi: 10.1016/j.antiviral.2020.104873.
    >> Share

    June 2020
  45. JOCKUSCH S, Tao C, Li X, Anderson TK, et al
    A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
    Antiviral Res. 2020;180:104857.
    >> Share

  46. SHANNON A, Le NT, Selisko B, Eydoux C, et al
    Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.
    Antiviral Res. 2020;178:104793.
    >> Share

    May 2020
  47. TAI W, Zhang X, He Y, Jiang S, et al
    Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.
    Antiviral Res. 2020 May 13:104820. doi: 10.1016/j.antiviral.2020.104820.
    >> Share

    April 2020
  48. MANTLO E, Bukreyeva N, Maruyama J, Paessler S, et al
    Antiviral activities of type I interferons to SARS-CoV-2 infection.
    Antiviral Res. 2020;179:104811.
    >> Share

  49. BRAY M, Rayner C, Noel F, Jans D, et al
    Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.
    Antiviral Res. 2020 Apr 21:104805. doi: 10.1016/j.antiviral.2020.104805.
    >> Share

  50. SALLARD E, Lescure FX, Yazdanpanah Y, Mentre F, et al
    Type 1 interferons as a potential treatment against COVID-19.
    Antiviral Res. 2020;178:104791.
    >> Share

  51. TANG T, Bidon M, Jaimes JA, Whittaker GR, et al
    Coronavirus membrane fusion mechanism offers as a potential target for antiviral development.
    Antiviral Res. 2020 Apr 6:104792. doi: 10.1016/j.antiviral.2020.104792.
    >> Share

  52. CALY L, Druce JD, Catton MG, Jans DA, et al
    The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro.
    Antiviral Res. 2020 Apr 3:104787. doi: 10.1016/j.antiviral.2020.104787.
    >> Share

  53. CHOY KT, Yin-Lam Wong A, Kaewpreedee P, Sia SF, et al
    Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
    Antiviral Res. 2020 Apr 3:104786. doi: 10.1016/j.antiviral.2020.104786.
    >> Share

    March 2020
  54. TOURET F, de Lamballerie X
    Of chloroquine and COVID-19.
    Antiviral Res. 2020;177:104762.
    >> Share

  55. SIGRIST C, Bridge A, Le Mercier P
    A potential role for integrins in host cell entry by SARS-CoV-2.
    Antiviral Res. 2020 Mar 1:104759. doi: 10.1016/j.antiviral.2020.104759.
    >> Share

    February 2020
  56. COUTARD B, Valle C, de Lamballerie X, Canard B, et al
    The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade.
    Antiviral Res. 2020;176:104742.
    >> Share

  57. CLASMAN JR, Everett RK, Srinivasan K, Mesecar AD, et al
    Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease.
    Antiviral Res. 2020;174:104661.
    >> Share

    January 2020
  58. NIU J, Shen L, Huang B, Ye F, et al
    Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice.
    Antiviral Res. 2020;173:104646.
    >> Share

  59. MA-LAUER Y, Zheng Y, Malesevic M, von Brunn B, et al
    Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication.
    Antiviral Res. 2020;173:104620.
    >> Share

    December 2019
  60. THEERAWATANASIRIKUL S, Kuo CJ, Phetcharat N, Lekcharoensuk P, et al
    In silico and in vitro analysis of small molecules and natural compounds targeting the 3CL protease of feline infectious peritonitis virus.
    Antiviral Res. 2019;174:104697.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016